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Marek’s disease (MD) infection has been controlled effectively by vaccination using nononcogenic and/or attenuated
oncogenic Marek’s disease virus (MDV) vaccines. Thus far, there is little knowledge on the role of cell-mediated immune
(CMI) responses during MDV infection or vaccination. To elucidate the importance of MDV proteins in CMI responses, the
pp38, Meq, ICP4, or ICP22 genes of an oncogenic strain, GA and the gB, ORF A, A41, or L1 genes of a highly oncogenic
strain, RB1B were stably transfected into reticuloendotheliosis virus (REV)-transformed lymphoblastoid cells, CU-91 (MHC:
B19B19) and CU-205 (MHC: B21B21). Cell lines positive for MDV gene transcription and/or protein expression were used in a
standard 4-hr chromium release assay. Effector cells for this assay were obtained from splenocytes of chickens infected
with the oncogenic strain, JM-16/13 or the nononcogenic vaccine strain, SB-1/12. Cell lines expressing MDV pp38, Meq,
or gB were lysed by syngeneic but not allogeneic MDV-sensitized splenocytes obtained from chickens of B19B19 and B21B21
haplotypes. However, syngeneic CMI responses against ICP4 were detected only in B21B21 chickens. CMI responses were
not detected against B19B19 and B21B21 cell lines expressing A41, L1, ORF A, or ICP22. This report suggests that syngeneic
CMI responses against pp38, Meq, ICP4, and gB of GA and RB1B strains, respectively, can be induced in chickens inoculated
with JM16/13 or SB-1/12. The difference in CMI response to ICP4 in genetically susceptible (B19B19) and genetically resistant
(B21B21) chickens may be an important factor in genetic resistance. q 1996 Academic Press, Inc.
INTRODUCTION BamHI-H family [open reading frame (ORF) A, B, C, D, E,
and F] have also been cloned and sequenced (Chen et
Marek’s disease (MD), an economically important, T
al., 1992; Hong and Coussens, 1994; Jones et al., 1992;
cell lymphoproliferative disease in chickens is caused by
Ohashi et al., 1994a, 1994b; Peng et al., 1992). Depending
Marek’s disease virus (MDV), an oncogenic herpesvirus on the host major histocompatibility (MHC) genes, the
(Churchill and Biggs, 1967). MDV can be divided into majority of cytotoxic T lymphocytes (CTLs) during alpha-
three serotypes; MDV serotype 1 (MDV-1) consists of all herpesvirus infections in mice are directed against IE
oncogenic and attenuated strains, MDV serotype 2 and/or L genes products (Banks et al., 1991; Hanke et
(MDV-2) consists of naturally occurring nononcogenic al., 1991; Martin et al., 1990; Witmer et al., 1990). For
strains, and MDV serotype 3 (MDV-3) consists of non- example in HSV-1 infection, ICP27 and ICP4 were target
pathogenic strains from turkeys and is known as herpes- antigens for CTLs in mice of H-2d and H-2k haplotypes,
virus of turkey (HVT) (reviewed by Schat, 1987). respectively (Banks et al., 1991; Martin et al., 1990). Con-
MDV and HVT were initially classified as gammaher- versely, gB-specific CTLs were only detected in mice of
pesviruses on the basis of their biological properties. H-2b and H-2d haplotypes (Hanke et al., 1991; Witmer et
However, the overall genome structures of MDV and HVT al., 1990).
are closely related to alphaherpesviruses (Buckmaster Although significant progress has been made in
et al., 1988). MDV genes with homology to herpes sim- characterizing MDV genes (reviewed by Zelnik, 1995)
plex virus type 1 and 2 (HSV-1 and HSV-2) genes encod- and MD infection has been controlled effectively by
ing for immediate early (IE) genes, ICP4, ICP22, ICP27 vaccination of chicks at 1 day of age using one or more
and late (L) genes, gB, gC, gD, gE, gH, gI, gK, and gL serotypes (Okazaki et al., 1970; Schat and Calnek, 1978;
have been cloned and sequenced (Anderson et al., 1992; Witter et al., 1984), limited information is available on
Binns and Ross, 1989; Brunovskis and Velicer, 1995; Ren the importance of individual MDV antigens in the induc-
et al., 1994; Ross et al., 1989; Sakaguchi et al., 1992; tion of CMI responses and protective immunity. The
Scott et al., 1993; Yoshida et al., 1994). Genes unique to study of cell-mediated immune (CMI) responses during
MDV, pp38, pp14, Meq, A41, L1, and 1.69-kb cDNA of MD infection has been problematic due to the lack of
MHC-defined target cells for use in cytotoxicity assays.
Numerous investigators have used MD-tumor cell lines1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (607) 253-3384. E-mail: kas24@cornell.edu. as target cells demonstrating in vitro lysis of allogeneic
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but not syngeneic target cells by T cells obtained from expression vectors. MDV genes encoding for pp38, Meq,
L1, ICP22, or gB were obtained by using DNA polymerasechickens inoculated with MDV-1 (Calnek et al., 1979;
Powell et al., 1983), MDV-2 (Schat and Calnek, 1980; chain reactions (PCRs). The templates and oligonucleo-
tide primers used in amplifying these MDV genes areSchat et al., 1982b), or HVT (Sharma et al., 1977). The
use of MDV-infected chicken kidney cells (CKC) as tar- shown in Table 1. The MDV gB and ICP22 open reading
frames (ORFs) were obtained from MDV-1 strains, RB1Bget cells in cytotoxicity assays is also not very success-
ful (Schat and Heller, 1985). In the avian system, synge- and GA-infected CKC DNA, respectively (Schat et al.,
1982a). The L1 ORF was generated from CU-41, a RB1B-neic MHC-restricted virus-specific CD8/ CTLs have
been demonstrated in spleens of chickens infected transformed nonexpression cell line DNA (Ohashi et al.,
1994a). The pp38 gene was amplified from pMD11, whichwith reticuloendotheliosis virus (REV) (Lillehoj et al.,
1988; Maccubbin and Schierman, 1986; Weinstock et contains a 5-kb fragment of BamHI-H region of MDV
genome which was kindly provided by P. J. A. Sonder-al., 1989). Recently, MHC-restricted, CD8/ virus-spe-
cific CTLs have been demonstrated during avian leuko- meijer (Intervet, Boxmeer, The Netherlands). The Meq
gene was amplified from RCAS-Meq, which contains asis virus (ALV) infection (Thacker et al., 1995). Pre-
viously, we developed a system in which we were able 1395-bp ClaI fragment encoding for Meq which was a
gift from H-J. Kung (Case Western University, Cleveland,to transfect and express the MDV pp38 gene in REV-
transformed lymphoblastoid cell lines. These cell lines OH). As shown in Table 1, upstream and downstream
oligonucleotide primers complementary to the 5* and 3*have been used successfully to demonstrate that syn-
geneic but not allogeneic MDV-sensitized splenocytes ends of pp38 (Chen et al., 1992), Meq (Jones et al., 1992),
L1 (Ohashi et al., 1994a), and ICP22 (Sakaguchi et al.,lyse these target cells (Pratt et al., 1992; Uni et al.,
1994). 1992) genes, respectively, were designed with HindIII
and XbaI sites for PCR subcloning. Upstream and down-To elucidate the importance of individual MDV proteins
in CMI responses, we cloned MDV genes pp38, Meq, stream oligonucleotide primers complementary to the 5*
and 3* ends of gB gene (Ross et al., 1989) were designedgB, ICP4, ICP22, ORF A, A41, or L1 into an eukaryotic
expression vector and transfected them into REV-trans- with SpeI and NotI sites, respectively. The amplified prod-
ucts of HindIII– XbaI fragments of pp38, Meq, L1, ICP22,formed lymphoblastoid cell lines, CU-91 (B19B19) and CU-
205 (B21B21). We demonstrated syngeneic but not alloge- and SpeI–NotI gB fragment were ligated into a plasmid,
pBluescript (II) KS(/) [pBS/KS(/)] (Stratagene, La Jolla,neic CMI responses against pp38, Meq, and gB in chick-
ens of B19B19 and B21B21 haplotypes. Interestingly, CMI CA), termed pBS/KS-pp38, pBS/KS-Meq, pBS/KS-L1, pBS/
KS-ICP22, and pBS/KS-gB, respectively, and were se-responses against ICP4 were only detected in chickens
with B21B21 haplotype, which is a MD-resistant line. MDV- quenced completely by using the dideoxy chain termina-
tion method to verify their sequences (Sequenase ver-specific CMI responses were not detected against
ICP22, ORF A, A41, or L1 in chickens of both haplotypes. sion 2.0 DNA sequencing kit, United States Biochemical,
Cleveland, OH).
The pBS/KS-pp38, pBS/KS-Meq, pBS/KS-L1, and pBS/MATERIALS AND METHODS
KS-ICP22 plasmids were digested with HindIII and XbaI
Animals and the 938 bp of pp38, 1155 bp of Meq, 468 bp of L1,
or 573 bp of ICP22 fragments were subcloned into pRc/Specific pathogen-free chickens of P2a (B19B19) and
CMV to generate pRc/CMV-pp38, pRc/CMV-Meq, pRc/N2a (B21B21) lines were obtained from the departmental
CMV-L1, or pRc/CMV-ICP22, respectively. The pBS/KS-flocks at Cornell University (Weinstock and Schat, 1987).
gB plasmid was digested with SpeI and NotI and the
2651 bp of gB fragment was subcloned into an eukaryoticViruses
expression vector, pRc/RSV (Invitrogen, San Diego, CA),
Nononcogenic MDV-2, SB-1 passage 12 (SB-1/12) was and termed pRc/RSV-gB. pRc/CMV-gB was obtained by
propagated in chicken embryo fibroblast (CEF) while an ligating the SpeI–NotI fragment of gB from pRc/RSV into
oncogenic MDV-1, JM-16 passage 13 (JM16/13), was pRc/CMV by using a NotI linker. The plasmid pRc/CMV-
propagated in chicken kidney cells (CKC) as previously A41 was generated by digesting the 641-bp A41 fragment
described (Schat et al., 1982b; Uni et al., 1994). The non- from pBS/KS-A41 (Ohashi et al., 1994b) with HindIII and
defective low-virulence CS-strain of REV (cs-REV) was XbaI. The pRc/CMV-ORF A plasmid was constructed by
propagated in CKC and was used as previously de- digesting the 201-bp ORF A fragment (Peng et al., 1992)
scribed (Weinstock et al., 1989). with HindIII and XbaI from pRc/RSV-ORF A, which was
kindly provided by M. Nonoyama (Tampa Bay ResearchPlasmid construction
Institute, St. Petersburg, FL). Plasmid pRc/CMV-ICP4 was
derived by digesting the plasmid pMD145 (Anderson etAn eukaryotic expression vector, pRc/CMV (Invitrogen,
San Diego, CA) was used for the construction of MDV al., 1992), which was kindly provided by R. Morgan (Uni-
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TABLE 1
Upstream and Downstream Oligonucleotide Primers Used in PCR Subcloning of Various MDV Open Reading Frames
Template Sequencea Nucleotide position MDV gene/size (bp)b
pMD11c 5*-GGGAAGCTTGTGATGGAATTCGAAGCAGAACAC*3 367 to 390 pp38/938
5*GGGCCCTCTAGAAATTCGCTTAATCTCCGCCTC*3 1271 to 1292
RCAS-Meqd 5*AAAAAGCTTGAGATGTCTCAGGAGCCAGAGC*3 161 to 182 Meq/1155
5*GGGCCCTCTAGACTTTAACCCTTTCCTTTAT*3 1289 to 1307
CU41 DNAe 5*GCAAGCTTCCGATACACAGGCACATAG*3 702 to 720 L1/468
5*CGTCTAGACGGCACTATCGGTACAACA*3 1142 to 1160
RB1B DNAf 5*GGGCCCACTAGTGCATCATTAAGATCATCTCA*3 028 to 03 gB/2651
5*GGCGGCCGCTCAGTTCAAATATAATAGTGCC*3 2600 to 2623
GA DNAf 5*AGGAAGCTTGGCAACATGAGTCGTGATCGA*3 2075 to 2095 ICP22/573
5*CCCGGGTCTAGACTCTTCAAGTCTGGATAGTTA*3 2618 to 2638
a The oligonucleotide primers are designed based on published sequences described under Materials and Methods. The sites used in PCR
subcloning are underlined and the start codon for pp38, Meq and ICP22 are in bold type. The start codon for L1 and gB are located upstream from
the shown sequence of the primers.
b The sizes of the amplified products are indicated in base pair (bp).
c Plasmid pMD11 contains a 5-kb fragment of BamHI-H region of MDV DNA, which was kindly provided by P. J. A. Sondermeijer (Intervert,
Boxmeer, The Netherlands).
d Plasmid RCAS-Meq consists of a 1395-bp ClaI fragment encoding for Meq was a gift from H-J. Kung (Case Western University, Cleveland, OH).
e CU-41, a MDV-1 strain, RB1B-transformed nonexpression cell line (Ohashi et al., 1994a).
f MDV-1 strains, RB1B and GA-infected chicken kidney cells DNA (Schat et al., 1982a).
versity of Delaware, Newark, DE) with BamHI and the tional in REV-transformed lymphoblastoid cell lines, a
reporter plasmid, pRc/CMV-lacZ was constructed by sub-4.2-kb ICP4 fragment was subcloned into the pRc/CMV
by using a NotI linker. The location and direction of tran- cloning the HindIII– XbaI fragment of the lacZ gene from
pCH110 (Pharmacia, Uppsala, Sweden) into pRc/CMV.scription of MDV genes used in this study are shown in
Fig. 1. In order to determine if the CMV promoter is func- All restriction enzyme reactions and subcloning proce-
dures were carried out as recommended by the manufac-
turer of the restriction enzymes and as previously de-
scribed (Sambrook et al., 1989).
DNA polymerase chain reaction
One hundred nanograms of template was added into
a 100-ml reaction-mixture containing 10 mM Tris–HCl
(pH 9.0 at 257), 50 mM KCl, 0.1% Triton X-100, 1.5 mM
MgCl2 , 0.2 mM of each deoxynucleoside triphosphate,
1.0 mM of each oligonucleotide primer, and 2.0 U of Tli
DNA polymerase with the proof-reading mechanisms
(Promega, Madison, WI). The reaction mixture was sub-
jected to 35 cycles of amplification (947 for 1 min, 457 for
2 min, and 727 for 1 min).
Preparation of plasmid DNA, transfection,
b-galactosidase assays, and establishment
of stable cell lines
Plasmids for transfection were prepared by using QIA-
GEN plasmid midi kit (Qiagen Inc., Studio City, CA).FIG. 1. Physical map of the MDV alphaherpesvirus genome structure
(Buckmaster et al., 1988). The MDV genome consists of a unique long Transfection of REV-transformed lymphoblastoid cell
(UL) region, flanked by a terminal repeat long (TRL), and an internal lines was performed as previously described (Schat et
repeat long (IRL), and a unique short (US) region, flanked by an internal al., 1992). Briefly 4 1 106 REV-transformed lymphoblas-
repeat short (IRS) and a terminal repeat short (TRS). Restriction sites,
toid cells, CU-91 (B19B19) an CU-205 (B21B21) were resus-B  BamHI and E  EcoRI. The location of the BamHI-K3, I3, A, H, I2,
pended in 0.4 ml of LM base medium (Schat et al., 1992)Q2, and L fragments of MDV genome and the direction of transcription
of gB, ICP4, ICP22, pp38, ORF A, Meq, A41, and L1 are shown. with 5 mg of linearized plasmid in a 0.4-cm sterilized
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cuvette, transfected by electroporation using the Gene enhancer region, the polyadenylation signals, the MDV
gene, or the neomycin gene of the plasmids. The di-Pulser Apparatus (Bio-Rad, Richmond, CA) set at 300 V
with capacitance extender set at 500 mF and were left gested DNA were electrophoresed on a 0.8% agarose
and transferred to Magnagraph nylon membranes (Mi-at room temperature for 10 min. Cells were resuspended
in 4 ml of LM base with 10% fetal bovine serum (FBS) cron Separations, Inc., Westborough, MA) by Southern
blotting (Sambrook et al., 1989).(LM10) (GIBCO BRL, Grand Island, NY) and incubated at
417. Fourty-eight hours after transfection, 500 to 1400 mg/ A neomycin-specific probe was prepared by digesting
pRc/CMV with SmaI and BstBI and was used to hybridizeml of active G418 (Life Technologies Inc., Grand Island,
NY) was added. Media were changed every 2 to 3 days. to CU-366 and CU-359 DNA. Specific probes for pp38,
Meq, A41, L1, ORF A, and ICP22 were prepared by digest-Selections were carried out for 3 to 4 weeks. G418-resis-
tant cells were biologically cloned by limiting dilution ing pRc/CMV-pp38, pRc/CMV-Meq, pRc/CMV-A41, pRc/
CMV-L1, pRc/CMV-ORF A, and pRc/CMV-ICP22 plas-cloning. For the transient expression of lacZ, 10 mg of
supercoiled pRc/CMV-lacZ was used and 48 hr after mids, respectively, with HindIII and XbaI and were used
to hybridize the DNA obtained from the cell linestransfection cells were pooled, fixed with acetone:metha-
nol (1:1) and stained with 1 mg/ml of 5-bromo-4-chloro-3- transfected with the corresponding MDV gene. The ICP4-
specific probe was prepared by digesting the plasmidindolyl-b-D-galactopyrano-side (X-gal) (Sigma Chemical
Co., St. Louis, MO) and 5 mM K4Fe (CN)6r3H2O, and 5 pRc/CMV-ICP4 with NotI and was used to hybridize CU-
373 and CU-375 DNA. CU-371 and CU-368 DNA weremM K4Fe(CN)6 . The slides were rinsed in 10 mM Tris-
buffered saline (pH 8.7) (PBS) and examined microscopi- hybridized with a gB-specific probe which was prepared
by digesting pRc/CMV-gB with NotI. The digested plas-cally for blue staining cells.
mids were electrophoresed on a 1.0% SeaKam Le agar-
Nomenclature of cell lines ose gel (FMC bioproducts, Rockland, ME) and the MDV
fragments were gel purified by using DNA purification
Cell lines are identified following the standard nomen-
QuicKit (National Scientific Supply, San Rafael, CA) and
clature for avian cell lines (Witter et al., 1979). Briefly, a
labeled with [32P]dCTP by using a multiprime DNA label-
two-letter abbreviation identifies the transforming virus
ing kit (Amersham Corp. Amersham, UK).
(RE), and two-letter abbreviation identifies the line as a
chicken cell line (CC). This four-letter code is followed
Isolation of cellular RNA and reverse transcriptaseby a two-letter abbreviation for the place of origin (Cornell
polymerase chain reactionUniversity (CU)) and a sequential number (e.g., CU-91).
Stably transfected cell lines received a new number.
Total cellular RNA from nontransfected and MDV-
Nontransfected and MDV-transfected REV-transformed
transfected REV-transformed lymphoblastoid cells were
lymphoblastoid cells which were used as target cells in
isolated using RNAzol B method (BIOTECX Laboratories
4-hr chromium release assays (CRAs) are summarized
Inc., Houston, TX). Briefly, precipitated RNA samples
in Table 2. REV-transformed lymphoblastoid cell lines
were washed with 75% ethanol and reconstituted in di-
(RECC) CU-91 and CU-205 were established from a P2a
ethylpyrocarbonate (DEPC)-treated water, and the RNA
(B19B19) and a N2a (B21B21) chicken, respectively (Schat
concentrations were determined by measuring the A260et al., 1992). All cell lines were maintained in LM 10 as
value. The RNA samples were treated with 200 mg/ml of
previously described (Uni et al., 1994) and stably
ribonuclease-free DNAse I (Promega, Madison, WI) at
transfected cell lines were maintained in LM 10 with 300
377 for 1 hr. All RNA preparations were stored in aliquots,
mg of active G418.
precipitated with an equal volume of ethanol, and stored
at 0707. Approximately 2 mg of DNAse-treated RNA sam-Southern hybridization
ples were used in reverse transcriptase polymerase
chain reactions (RT-PCRs) using the GeneAmp RNA PCRTotal DNA was extracted from parent and MDV-
transfected cell lines (Table 2) by standard procedure kit (Perkin–Elmer–Cetus, Norwalk, CT), following the
protocol provided by the manufacturer. Samples were(Sambrook et al., 1989). Twelve micrograms of DNA from
CU-364 and CU-362 (pp38/), CU-365 and CU-376 also amplified without the RT step to demonstrate the
absence of DNA. Upstream and downstream oligonucle-(A41/), CU-371 and CU-368 (gB/), CU-374 and CU-378
(ICP22), CU-370 and CU-377 (ORF A/), and CU-366 and otide primers complementary to the internal coding re-
gion of the 5* and 3* region of the MDV genes, respec-CU-359 (neo/) cell lines were digested overnight with
Bgl II. DNA from CU-363 and CU-369 (Meq/) and CU- tively, are shown in Table 3. To ensure the specificity of
the PCR products, the amplified products were resolved372 and CU-367 (L1/) were digested overnight with XmnI
and CU-373 and CU-375 (ICP4/) DNA were digested in 2.0% SeaKam Le agarose gel (FMC bioproducts, Rock-
land, ME), transferred to nylon membranes, and probedovernight with MunI. These restriction enzymes linear-
ized the transfected plasmids outside the CMV promoter/ simultaneously with the Southern blot membranes.
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Antibodies and indirect immunofluorescent antibody target cells with effector/target cell (E/T) ratio of 100:1
for 4 hr at 387. All cell lines were tested in two indepen-assay
dent assays using splenocytes from REV-, JM16/13-, and
Indirect immunofluorescent antibody assays (IIFAs) SB-1/12-infected chickens. Following a 4-hr incubation,
were used to detect the expression of MDV pp38, Meq, supernatants and pellets were separately harvested and
gB, and A41 antigens. Monoclonal antibodies against counts per minute (cpm) were counted in a Beckman
pp38 (H19.47) (Yanagida et al., 1992) (1:3000) and gB Gamma 4000 counter (Beckman Instruments, Inc., Fuller-
(IAN86) (Yanagida et al., 1992) (1:64) were kindly provided ton, CA) for 5 min. Each assay was performed in triplicate,
by L. F. Lee (Avian Disease and Oncology Laboratory, and the spontaneous release was less than 25% of the
East Lansing, Michigan). Rabbit polyclonal antibody total release by treatment with detergent in all assays.
against Meq protein (Jones et al., 1992) was kindly pro- The percentage-specific release (%SR) was calculated
vided by H-J. Kung (Case Western University, Cleveland, with the following formula:
OH) and was used at 1:40 dilution. Detection of A41
antigen was carried out by using a chicken polyclonal
%SRantibody (1:80) raised against glutathione S-transferase
fusion proteins which contain a portion of the A41 se-
quence (Ohashi et al., 1994b). Briefly, acetone:methanol 
cpm supernatant of target cells with effector
cells from SB-1 or JM-16 infected chickens 0 X
Y 0 X(1:1)-fixed cells were incubated with monoclonal or poly-
clonal antibody for 30 min at 377, washed in phosphate 1 100buffer saline (PBS), pH 7.2, for 15 min, and incubated
with fluorescein isothiocyanate (FITC)-conjugated rabbit
in which X is the mean of the cpm in the supernatant ofanti-mouse (1:100), FITC-conjugated goat anti-rabbit
uninfected chickens and Y is the mean of the total re-(1:100) or FITC-conjugated rabbit anti-chicken (1:100)
lease calculated by incubating an equivalent number ofsecondary antibodies (Kirkegaard & Perry Laboratories,
labeled target cells and effector cells with 2% sodiumInc., Gaithersburg, MD). Cells were examined with a Leitz
dodecyl sulfate. The mean percentage-specific releaseDialux fluorescence microscope equipped with epi-illu-
(%SR) values were compared using Student’s t testmination.
(Snedecor and Cochran, 1971).
Chromium release assay
RESULTS
Nontransfected and MDV-transfected REV-transformed
Transient expression of lacZ and establishment oflymphoblastoid cells were used as target cells in 4-hr chro-
stably transfected REV-transformed lymphoblastoidmium release assays (CRAs). The target cells were centri-
cell linesfuged 24 hr before the assay at 1500 rpm for 15 min over
a Ficoll-Hypaque gradient (Pharmacia, Uppsala, Sweden)
The expression of lacZ gene could be detected be-
and seeded at 106 cells per ml. On the day of the assay, the
tween 24 and 48 hr after transfection, indicating that the
target cells were centrifuged again over a Ficoll-Hypaque
CMV promoter is functional in REV-transformed lymph-
gradient, washed in PBS, pH 7.2, and incubated for 45 min
oblastoid cells. The level of lacZ expression was deter-
at 387 with 150–200 mCi of Na51CrO4 (sp act, 200 to 400 mined by counting the number of cells stained blue over
Ci/mg, New England Nuclear, Boston, MA) per 107 cells
the total number of cells. Transfection of CU-91 and CU-
per ml of LM20 (RPMI 1640 / 20% FBS). Afterwards cells
205 with pRc/CMV-lacZ resulted in 2% and 3 to 4% of
were washed seven times in LM20 and resuspended in
cells expressing lacZ, respectively. For the establishment
LM20 at 0.5 1 106 cells/ml.
of stable cell lines, transfected cells surviving the G418
The preparation of effector cells, conditions of CRAs,
selection were examined for MDV expression by IIFAs
and the calculations of percentage-specific release have
and/or RT-PCRs. Cells that were positive for MDV tran-
previously been described (Schat et al., 1982b). Briefly,
scription and/or expression were stored in liquid nitrogen
spleens were decapsulated and forced through a 60-mm
and a portion of the cells were biologically cloned by
pore size mesh (Tetko, Inc., Elmsford, NY). Spleen cells
limiting dilution. Stably transfected cell lines are listed in
were washed in PBS, pH 7.2, and were centrifuged at
Table 2.
1500 rpm for 20 min over a Ficoll-Hypaque gradient. In
all experiments six birds/treatment were used. Effector Detection of transfected MDV genes in MDV-
cells were obtained from spleens 7 days postinfection transfected REV-transformed lymphoblastoid cells
with 104.2 tissue culture infective dose 50% of cs-REV, or
1000 focus-forming units of JM16/13 or SB-1/12. Control Southern blot analyses of the transfected cell lines
confirmed the presence of the transfected plasmids ap-effector cells were obtained from uninfected hatchmates.
The CRA was performed by incubating 50,000 labeled parently integrated at one or more unique sites (Fig. 2).
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TABLE 2 3A), 457 (Fig. 3B), 173 (Fig. 3C), 260 (Fig. 3D), 526 (Fig.
3E), 608 (Fig. 3F), 224 (Fig. 3G), and 191 (Fig. 3H) bpNontransfected and MDV-Transfected REV-Transformed
were detected from CU-364 and CU-362 (pp38/), CU-Lymphoblastoid Cell Lines
363 and CU-369 (Meq/), CU-365 and CU-376 (A41/),
Transfected CU-371 and CU-368 (gB/), CU-374 and CU-378
B19B19 cell line B21B21 cell line plasmid (ICP22/), CU-373 and CU-375 (ICP4/), CU-372 and CU-
367 (L1/), and CU-370 and CU-377 (ORF A/) RNA, re-CU-91 CU-205 none
spectively, after hybridization with the correspondingCU-366 CU-359 pRc/CMV
CU-364 CU-362 pRc/CMV-pp38 MDV genes as specific DNA probes. Bands were not
CU-363 CU-369 pRc/CMV-Meq detected in PCR products from the total RNA samples
CU-365 CU-376 pRc/CMV-A41 isolated from MDV-transfected cell lines in the absence
CU-371 CU-368 pRc/CMV-gB
of reverse transcriptase or when PCR products wereCU-374 CU-378 pRc/CMV-ICP22
used from the parent cell lines, CU91 and CU-205.CU-373 CU-375 pRc/CMV-ICP4
CU-372 CU-367 pRc/CMV-L1
CU-370 CU-377 pRc/CMV-ORF A Expression of MDV genes in transfected REV-
transformed lymphoblastoid cell lines
Based on the IIFAs, the staining patterns of the differ-DNA extracted from nontransfected cell lines, CU-91 and
CU-205, did not hybridize with probes prepared from ent MDV proteins in MDV-transfected REV-transformed
lymphoblastoid cells were the same as in MDV-infectedpp38, Meq, A41, gB, L1, ICP22, ICP4, ORF A, or neomycin
[data not shown, except for pp38 (Fig. 2, lanes 1 and 2)]. CEF and MDV-infected CKC (Ohashi et al., 1994b; Yanag-
ida et al., 1992). Most cell lines expressed the MDV pro-The specificity of the Southern blots (Fig. 2) was con-
firmed by the hybridization of each probe to the linearized teins in 40 to 60% of the cells. As shown in Fig. 4A, cell
lines transfected with pp38 stained predominately in theexpression plasmid.
Transcription of the individually transfected MDV cytoplasmic region while Meq protein was detected in
the nucleus (Fig. 4C). The expression of A41 protein wasgenes were confirmed by RT-PCRs using oligonucleotide
primers described in Table 3. Ten microliters of RT-PCR also localized in the cytoplasma (Fig. 4E). gB protein was
predominately expressed in the cytoplasma and had aproducts from 2 mg of total RNA isolated from cell lines
with and without reverse transcriptase were analyzed by granular appearance (Fig. 4G). Nontransfected cells did
not stain with antibodies against pp38, Meq, A41, andgel electrophoresis. As expected, fragments of 313 (Fig.
FIG. 2. Detection of integrated transfected plasmids by Southern blot analysis. Genomic DNA from each indicated cell line was digested with
Bgl II (lanes 1 to 5, 9 to 17, and 24 to 29), XmnI (lanes 6 to 8 and 21 to 23), or MunI (lanes 18 to 20), which cuts once within the transfected
expression vectors. The data from nontransfected cells, CU-91 and CU-205 hybridized with Meq, A41, L1, gB, ICP22, ICP4, ORF A, or neomycin
except pp38 were not shown. The specificity of this Southern blot was verified by the detection of fragments of expected sizes (lanes 5, 8, 11, 14,
17, 20, 23, 26, and 29) from the linearized expression vectors. Molecular size markers are indicated in kilobases on the left.
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TABLE 3
Primers Used in RT-PCR for the Amplification of MDV RNA from MDV-Transfected REV-Transformed Lymphoblastoid Cells
Template Sequencea Nucleotide position Size of MDV fragment (bp)b
pp38 5*ATGCTGGCCGAAAGACA*3 905 to 921 313
5*TCTCCAGATTCCACCTC*3 1202 to 1218
Meq 5*AAAAGTCACGACATCCCCAAC*3 255 to 275 457
5*AAAGTTCCTCCGTATCGGGAG*3 692 to 712
A41 5*CATTGCTCGATAATCGCGTAG*3 848 to 868 173
5*GGGCTGAAGGAATTCGAAAGT*3 1001 to 1021
gB 5*TGAAGCGTTTGACAGGGATGC*3 819 to 839 260
5*TCTGGTGGGGATAGACCATAA*3 1059 to 1079
ICP22 5*ATGAGTCGTGATCGAGATCG*3 2081 to 2100 526
5*CTGTCTACCGACAAATCGTT*3 2588 to 2607
ICP4 5*CCTGAGACTTCACCGTCAAAT*3 1636 to 1656 608
5*GCCATGGGATGTGTTGAATCT*3 2224 to 2244
L1 5*AGTAATCTGCGTTAAGTCGTTA*3 805 to 826 224
5*GTAAACAATGCCACATCGTAGA*3 1008 to 1029
ORF A 5*ATGATGAAGCGGTTCGTC*3 141 to 158 191
5*TCAGCCCATCCTTTCTAC*3 315 to 332
a Oligonucleotide primers are designed based on published sequences described under Materials and Methods.
b The sizes of amplified products are indicated in base pair (bp).
gB (Fig. 4B, 4D, 4F, and 4H, respectively). The expression experiments were conducted in which splenocytes ob-
tained from P2a (B19B19) and N2a (B21B21) chickens wereof ORF A, L1, ICP4, and ICP22 proteins from cell lines
transfected with the corresponding MDV genes could not used. Both, syngeneic as well as allogeneic combina-
tions of effector and target cells were tested in the samebe examined since antibodies against these proteins are
not yet available. experiment. As shown in Table 6, only syngeneic but not
allogeneic target cells were associated with statistically
Induction of syngeneic virus-specific CMI responses significant lysis by virus-specific splenocytes. P2a splen-
after inoculation of chickens with REV or JM16/13 or ocytes (B19B19) from JM16/13-sensitized chickens (Expt
SB-1/12 9) lysed only syngeneic [CU364 (pp38/) (P  0.02) and
CU-371 (gB/) (P  0.005)] but not allogeneic [CU-362
As shown in Tables 4 and 5, the cytotoxic activity of (pp38/) and CU-368 (gB/)] cell lines. Conversely, the
spleen cells obtained from B19B19 (Expts 1 to 4) and B21B21 same observations were obtained when N2a spleno-
(Expts 5 to 8) chickens immunized with REV, JM16/13, or cytes (B21B21) were used (Expt 10). N2a splenocytes
SB-1/12 was examined against parent and MDV- (B21B21) from JM16/13-sensitized chickens were able to
transfected REV-transformed lymphoblastoid cell lines in lyse the syngeneic (CU-375) (P  0.005) but not the allo-
two trials. Cell lines expressing pp38 [CU-364 (Expt 1) geneic (CU-373) cell line expressing ICP4 (Expt 10). In
and CU-362 (Expt 5)] and gB [CU-371 (Expt 3) and CU- contrast, P2a splenocytes (B19B19) did not lyse the synge-
368 (Expt 7)] were lysed by JM16/13 or SB-1/12-sensitized neic CU-373 cell line, while the same splenocytes did
splenocytes (P 0.01 to P 0.005) obtained from chick- lyse syngeneic cell lines expressing gB (CU-371) and
ens of B19B19 and B21B21 haplotypes, respectively. Low pp38 (CU-364) (Expt 9). All nontransfected and MDV-
levels of syngeneic MDV-sensitized CMI responses (P transfected cell lines were efficiently lysed by syngeneic 0.05) were also detected against cell lines expressing but not allogeneic REV-specific splenocytes at significant
Meq [CU-363 (Expt 1) and CU-369 (Expt 6)]. However, levels (P  0.005 to P  0.001) except for CU-364 and
we could only demonstrate syngeneic CMI responses CU-375. The REV-specific lysis of CU-364 (pp38/) in Expt
against ICP4 in the B21B21 cell line [CU-375 (P  0.005) 1 and CU-375 (ICP4/) in Expt 7 were significantly lower
(Expt 7)] but not in the B19B19 cell line expressing ICP4 (P  0.01) than the nontransfected parent cells and pRc/
[CU-373 (Expt 4)]. Cell lines of B19B19 and B21B21 haplo- CMV-transfected cell lines (P  0.005 to P  0.001).
types expressing A41 (Expts 2 and 8), L1 (Expts 3 and
6), ORF A (Expts 3 and 7), or ICP22 (Expts 4 and 8) DISCUSSION
were not lysed by splenocytes obtained from chickens
inoculated with JM16/13 or SB-1/12. The ability of attenuated oncogenic and nononcogenic
MDV vaccines to confer protection against different on-In order to ensure that the pp38, gB, or ICP4 express-
ing cell lines are lysed in a MHC-restricted manner, two cogenic MDV challenge is well documented (reviewed
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FIG. 3. RT-PCR analysis of RNA extracted from nontransfected and MDV-transfected cell lines. Total cellular RNA extracted from each cell line
and the presence of RT in the experimental reactions are indicated at the top. Membranes A–H were hybridized with DNA probe of pp38, Meq,
A41, gB, ICP22, ICP4, L1, or ORF A, respectively. The sizes of the amplified products are in accord with the published sequence, indicated in base
pair (bp).
by Powell, 1985). However the protective antigens have sequences coding for immunological relevant nonapep-
tides.not been identified for the three serotypes of MDV. The
data presented in this study clearly show that syngeneic In all experiments using cell lines expressing pp38,
Meq, gB, or ICP4 at the E:T ratio of 100:1, a relativelyCMI responses against pp38, Meq, ICP4, and gB of GA
and RB1B strains, respectively, can be induced in chick- low, but significant level of specific release was detected.
It is not surprising to find rather low levels of specificens infected with JM16/13 or SB-1/12. However, chickens
inoculated with JM16/13 or SB-1/12 failed to lyse synge- release after a primary infection with viruses, because
the frequency of antigen-specific splenocytes is oftenneic cell lines expressing A41, L1, ORF A of RB1B strain
or ICP22 of GA strain. The JM16/13 and SB-1/12 strains low and high levels of specific release require in vitro
stimulation of primary splenocytes. Another reason forwere selected because they represent a serotype 1 (on-
cogenic) strain and a serotype 2 (nononcogenic) vaccine the relatively low levels of specific release could be the
fact that not all cells expressed the viral protein as wasstrain, respectively. Although not all MDV genes were
cloned from the same MDV strain for this study, it is demonstrated in the IIFA. The reason(s) for this lack of
expression in all cells was not determined, but could beunlikely that this would influence the results since recog-
nition of specific epitopes by CTL depends on the pres- cell-cycle dependent especially because all cell lines
had been biologically cloned. Moreover, the MDV-ence of specific nonapeptides (reviewed by Germain,
1994). Once these nonapeptides are identified it will be- transfected REV-transformed cell lines have comparable
low levels of REV- as well as MDV-specific releases.come feasible to examine the question if MDV strains
with differences in oncogenicity have differences in the Based on the CRA results (Table 6), it is unlikely that
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FIG. 4. Immunofluorescence analysis of MDV pp38-, Meq-, A41-, or gB-transfected cell lines. Expression of MDV pp38, Meq, A41, and gB proteins
from corresponding MDV-transfected cells are shown at A, C, E, and G, respectively. Nontransfected cells stained with antibody against pp38, Meq,
A41, or gB are shown at B, D, F, and H, respectively.
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TABLE 4
Lysis of REV-Transformed Lymphoblastoid Cell Lines (B19B19 ) Transfected with a Single MDV Gene by Splenocytes
Obtained from P2a (B19B19) Chickens inoculated with REV or SB-1/12 or JM16/13
% specific releasea of splenocytes obtained from chickens inoculated withb
Target cells Trial 1 Trial 2
Expt Line MDV gene REV JM16 SB-1 REV JM16 SB-1
1 CU-91 None 13c 2 2 9c 1 1
CU-366 pRc/CMV 14c 1 1 10c 1 NT
CU-364 pp38 6d 10c 8c 6d 8c 7d
CU-363 Meq 9c 7e 5e 12c 6e 6e
2 CU-91 None 11f 2 1 13c 2 2
CU-365 A41 14f 1 1 12c 1 1
CU-205g None 0 1 0 1 1 0
3 CU-91 None 16c 1 2 16c 1 0
CU-370 ORF A 13f 2 0 15c 3 1
CU-371 gB 15f 11d 12c 16c 15c 17c
CU-372 L1 10c 3 1 11c 2 0
4 CU-91 None 30f 2 0 23c 2 02
CU-373 ICP4 42f 3 1 25f 3 1
CU-374 ICP22 35f 3 2 20c 1 NT
CU-205g None 04 2 2 1 2 0
Note. NT, not tested.
a Spontaneous release from target cells did not exceed 25%.
b Six chickens/group were used, E/T ratios were 100:1.
c Significantly different (P  0.005) from control groups.
d Significantly different (P  0.01) from control groups.
e Significantly different (P  0.05) from control groups.
f Significantly different (P  0.001) from control groups.
g Allogeneic nontransfected target cells.
the effector cells in these assays were NK cells since Meq by inoculation with the nononcogenic SB-1 strain is
of interest, since Meq has only been identified in MDV-syngeneic but not allogeneic lysis could be demon-
strated. Moreover, REV-transformed cells express high 1 (Jones et al., 1992). Probably there is a SB-1 gene with
homology for Meq which has not yet been identified.levels of MHC class I and II antigens (Hrdlickova et al.,
1994). We are currently investigating the phenotype of Even though MD has been controlled effectively by
vaccination, the antigens associated with protective im-the effector cells associated with CMI responses against
cell lines expressing pp38, gB, and ICP4. In vitro deple- munity are poorly defined. It has been suggested that
most MD vaccines protect chickens independently of thetion studies using splenocytes from SB-1/12-infected
chickens indicate that the effector cells are CD8/ and MHC gene background (Bacon and Witter, 1993). How-
ever, vaccination confers superior protection in MD-re-TCRab1/ (manuscript in preparation).
The presence of CMI responses against pp38 in chick- sistant chickens compared to MD-susceptible chickens.
The mechanism of MHC-related resistance to MD isens inoculated with SB-1 indicate that the gene which
encodes for pp38 is not restricted to MDV-1 as previously poorly understood. However, it is clear that the level of
secondary cytolytic infection is markedly lower in geneti-proposed by Chen et al. (1992). Indeed, recently Ono et
al. (1994, 1995) reported that the MDV-2 strain HRPS-24 cally resistant, B21B21 chickens than the genetically sus-
ceptible, B19B19 chickens (reviewed by Calnek, 1985). Itencodes for a pp38-like gene which is homologous to
pp38 of MDV-1. In addition, the MDV-3 strain FC126 en- is attractive to postulate that the induction of ICP4-spe-
cific CMI responses in the B21B21 haplotype chickenscodes for a truncated form of pp38 protein which is highly
homologous to the C-terminal region of MDV-1 pp38 might play an important role in protective immunity by
inhibiting the secondary cytolytic infection and the subse-(Smith et al., 1995). These findings are in good agreement
with this study and our previous studies in which specific quent development of immortalized MDV-infected T lym-
phocytes.CMI responses against pp38 were demonstrated in
chickens inoculated with SB-1 or HVT (Pratt et al., 1992; The in vivo importance of CMI responses against pp38,
Meq, and gB in B21B21 and B19B19 is not yet known. Nazer-Uni et al., 1994). The induction of CMI responses against
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TABLE 5
Lysis of REV-Transformed Lymphoblastoid Cell Lines (B21B21) Transfected with a Single MDV Gene by Splenocytes
Obtained from N2a (B21B21) Chickens Inoculated with REV or SB-1/12 or JM16/13
% specific releasea of splenocytes obtained from chickens inoculated withb
Target cells Trial 1 Trial 2
Expt Line MDV gene REV JM16 SB-1 REV JM16 SB-1
5 CU-205 None 12c 3 1 13c 2 3
CU-359 pRc/CMV 20d 2 2 13d 2 2
CU-362 pp38 8c 9c 11c 10c 10c 9c
CU-91g None 01 1 2 0 2 2
6 CU-205 None 14c 2 1 15d 2 1
CU-367 L1 12c 2 0 13d 2 1
CU-369 Meq 13d 7e 5 14c 6e 5e
7 CU-205 None 20d 1 2 23d 1 1
CU-368 gB 25d 13c 12c 31d 12c 14c
CU-375 ICP4 8f 13c 13c 6f 14c 16c
CU-377 ORF A 22d 2 1 36d 4 0
CU-91g None 04 1 2 01 02 NT
8 CU-205 None 11c 1 0 14c 0 1
CU-378 ICP22 21c 3 4 14d 2 2
CU-376 A41 13c 2 02 15c 1 0
Note. NT, not tested.
a Spontaneous release from target cells did not exceed 25%.
b Six chickens/group were used, E/T ratios were 100:1.
c Significantly different (P  0.005) from control groups.
d Significantly different (P  0.001) from control groups.
e Significantly different (P  0.05) from control groups.
f Significantly different (P  0.01) from control groups.
g Allogeneic nontransfected target cells.
ian et al. (1992) reported that B2B15 chickens were pro- against gB. Recently, we have found that B19B19 chickens
vaccinated with rFPV-gB also produced gB-specific CMItected against challenge after immunization with recom-
binant fowlpox virus (rFPV) vaccines expressing gB responses (Omar, Schat, and Lee, unpublished data). It
is not surprising that chickens produce both CMI re-(rFPV-gB) but not with rFPV expressing pp38. These
chickens produced virus neutralizing (VN) antibodies sponses and VN antibodies against gB since mice in-
TABLE 6
Syngeneic MHC-Restricted Lysis of Nontransfected and MDV-Transfected REV-Transformed Lymphoblastoid Cell Lines
by Splenocytes Obtained from Chickens Inoculated with REV or JM16/13
% specific releasea
MHC B19B19 cell line B21B21 cell line
Effector CU-364 CU-371 CU-373 CU-362 CU-368 CU-375
Expt cell Virusb CU-91 (pp38/) (gB/) (ICP4/) CU-205 (pp38/) (gB/) (ICP4/)
9 B19B19 REV 11c 10c 15c 25d 0 1 2 0
JM16 1 6e 13c 2 1 1 2 3
10 B21B21 REV 01 2 0 01 15c 12c 13c 8e
JM16 02 0 0 01 2 11c 14c 18c
a Spontaneous release from target cells did not exceed 25%.
b Six chickens/group were used, E/T ratios were 100:1.
c Significantly different (P  0.005) from control groups.
d Significantly different (P  0.001) from control groups.
e Significantly different (P  0.02) from control groups.
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mice against lethal herpes simplex virus 1 infection. Proc. Natl. Acad.fected with HSV-1 developed protective gB-specific neu-
Sci. USA 84, 5908–5912.tralizing antibodies as well as NK cells and CD4/ and
Chen, X., Sondermeijer, P. J. A., and Velicer, L. F. (1992). Identification of
CD8/ T cells against lethal challenge of HSV-1 (Cantin a unique Marek’s disease virus gene which encodes a 38-kilodalton
et al., 1987; Ghiasi et al., 1994). phosphoprotein and is expressed in both lytically infected cells and
latently infected lymphoblastoid tumor cells. J. Virol. 66, 85–94.The ability of JM16/13- or SB-1/12-infected chickens
Churchill, A. E., and Biggs, P. M. (1967). Agent of Marek’s disease into recognize pp38, Meq, ICP4, and gB of GA and RB1B
tissue culture. Nature 215, 528–530.strains, respectively, indicate that there might be com-
Germain, R. N. (1994). MHC-dependent antigen processing and peptide
mon CMI epitopes among these serotypes. Serotype- presentation: Providing ligands for T lymphocyte activation. Cell 76,
cross-reactive CTL clones recognizing more than one 287–299.
Ghiasi, H., Kaiwar, R., Nesburn, A. B., Slanina, S., and Wechsler, S. L.serotype have been demonstrated in HSV (Booneau et
(1994). Expression of seven herpes simplex virus type 1 glycoproteinal., 1990) and dengue virus (Zivny et al., 1995) infections.
(gB, gC, gD, gE, gG, gH and gI): Comparative protection againstThe inability of JM16/13- or SB-1/12-sensitized chickens
lethal challenge in mice. J. Virol. 68, 2118–2126.
to lyse syngeneic cell lines expressing A41, L1, ORF A, Hanke, T., Graham, F. L., Rosenthal, K. L., and Johnson, D. C. (1991).
or ICP22 probably indicate that these genes do not play Identification of an immunodominant cytotoxic T-lymphocyte recogni-
tion site in glycoprotein B of herpes simplex virus by using recombi-a major role in inducing CMI responses.
nant adenovirus vectors and synthetic peptides. J. Virol. 65, 1177–
1186.
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